Trajectories in muscular strength and physical function among men with and without prostate cancer in the health aging and body composition study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
07
10
2019
accepted:
22
01
2020
entrez:
14
2
2020
pubmed:
14
2
2020
medline:
6
5
2020
Statut:
epublish
Résumé
To examine and compare changes in strength and physical function from pre- to post-diagnosis among men with prostate cancer (PC, [cases]) and matched non-cancer controls identified from the Health, Aging and Body Composition (Health ABC) study. We conducted a longitudinal analysis of 2 strength and 3 physical function-based measures among both cases and controls, identified from a large cohort of community living older adults enrolled in the Health ABC study. We plotted trajectories for each measure and compared cases vs. controls from the point of diagnosis onwards using mixed-effects regression models. For cases only, we examined predictors of poor strength or physical function. We identified 117 PC cases and 453 matched non-cancer controls (50% African Americans). At baseline, there were no differences between cases and controls in demographic factors, comorbidities or self-reported physical function; however, cases had slightly better grip strength (44.6 kg vs. 41.0 kg, p<0.01), quadriceps strength (360.5 Nm vs. 338.7 Nm, p = 0.02) and Health ABC physical performance battery scores (2.4 vs. 2.3, p = 0.01). All men experienced similar declines in strength and physical function over an equivalent amount of time. The loss of quad strength was most notable, with losses of nearly two-thirds of baseline strength over approximately 7 years of follow up. Among both cases and controls, strength and physical function decline with increasing age. The largest declines were seen in lower body strength. Regular assessments should guide lifestyle interventions that can offset age- and treatment-related declines among men with PC.
Identifiants
pubmed: 32053654
doi: 10.1371/journal.pone.0228773
pii: PONE-D-19-28019
pmc: PMC7017990
doi:
Banques de données
Dryad
['10.5061/dryad.47d7wm38z']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0228773Subventions
Organisme : NIA NIH HHS
ID : N01 AG062103
Pays : United States
Organisme : NIA NIH HHS
ID : N01 AG062106
Pays : United States
Organisme : NINR NIH HHS
ID : R01 NR012459
Pays : United States
Organisme : NIA NIH HHS
ID : N01 AG062101
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG059186
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG028050
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG021332
Pays : United States
Organisme : NIA NIH HHS
ID : R21 AG058249
Pays : United States
Organisme : NCI NIH HHS
ID : R25 CA122061
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA012197
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
CA Cancer J Clin. 2016 Jul;66(4):271-89
pubmed: 27253694
Prostate Cancer Prostatic Dis. 2009;12(2):198-203
pubmed: 18852703
J Gerontol A Biol Sci Med Sci. 2016 Mar;71 Suppl 1:S23-30
pubmed: 26858321
J Gerontol A Biol Sci Med Sci. 2009 Apr;64(4):462-7
pubmed: 19181715
BMJ Open. 2017 Jul 20;7(7):e016875
pubmed: 28729326
J Natl Cancer Inst Monogr. 2012 Dec;2012(45):152-6
pubmed: 23271766
Support Care Cancer. 2016 May;24(5):2201-2207
pubmed: 26563183
J Gerontol A Biol Sci Med Sci. 2001 Oct;56(10):M644-9
pubmed: 11584038
J Nutr Health Aging. 2018;22(8):938-943
pubmed: 30272097
Cancer. 2012 Nov 15;118(22):5679-87
pubmed: 22544633
Eur Urol. 2015 Jul;68(1):32-9
pubmed: 25457017
JAMA. 2009 May 13;301(18):1883-91
pubmed: 19436015
Res Rep Urol. 2016 Aug 16;8:133-43
pubmed: 27574584
Acta Oncol. 2015 Nov;54(10):1805-13
pubmed: 25927504
Urology. 2002 Sep;60(3 Suppl 1):7-11; discussion 11-2
pubmed: 12231037
J Community Support Oncol. 2014 Aug;12(8):278-92
pubmed: 25372364
Urol Oncol. 2017 May;35(5):234-242
pubmed: 28110975
J Oncol. 2015;2015:820403
pubmed: 26300918
J Clin Oncol. 2010 Dec 1;28(34):5038-45
pubmed: 21041715
Cancer Epidemiol Biomarkers Prev. 2017 Feb;26(2):179-187
pubmed: 27677728
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Sci Rep. 2018 May 30;8(1):8374
pubmed: 29849032
J Gerontol A Biol Sci Med Sci. 2006 Jan;61(1):72-7
pubmed: 16456196
Int J Behav Nutr Phys Act. 2004 Oct 29;1(1):16
pubmed: 15516261
J Clin Oncol. 2005 Aug 20;23(24):5814-30
pubmed: 16043830
Br J Cancer. 2015 Jan 6;112(1):194-8
pubmed: 25393366
J Am Geriatr Soc. 2010 Jan;58(1):76-82
pubmed: 20122042
Psychooncology. 2017 Oct;26(10):1576-1585
pubmed: 27943512
Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1468-76
pubmed: 19366909
Ann Behav Med. 2018 Apr 19;52(5):412-428
pubmed: 29684136
Cancer. 2016 Jun 15;122(12):1946-53
pubmed: 27159822
PLoS One. 2018 Dec 7;13(12):e0208581
pubmed: 30532212
J Clin Oncol. 2010 Nov 1;28(31):4687-96
pubmed: 20921463
Endocr Relat Cancer. 2014 Oct;21(5):R371-94
pubmed: 25056176
JAMA. 2014 Jun 18;311(23):2387-96
pubmed: 24866862